Vial T. French pharmacovigilance: Missions, organization and perspectives. Therapies. 2016;71:143–50.
Moore N, Berdaï D, Blin P, Droz C. Pharmacovigilance – The next chapter. Therapies. 2019;74:557–67.
Faillie J-L. Case-non case studies: Principles, methods, bias and interpretation. Therapie. 2018;73:247–55.
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29:385–96.
Costa C, Abeijon P, Rodrigues DA, Figueiras A, Herdeiro MT, Torre C. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm. 2023;
García-Abeijon P, Costa C, Taracido M, Herdeiro MT, Torre C, Figueiras A. Factors associated with underreporting of adverse drug reactions by health care professionals: A systematic review update. Drug Saf. 2023;46:625–36.
Article PubMed PubMed Central Google Scholar
Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis NMCD. 2018;28:533–42.
Article CAS PubMed Google Scholar
Mouly S, Roustit M, Bagheri H, Perault-Pochat M-C, Molimard M, Bordet R. The French Levothyrox® crisis: We did the best we could but…. Therapie. 2019;74:431–5.
Langlade C, Gouverneur A, Bosco-Lévy P, Gouraud A, Pérault-Pochat M-C, Béné J, et al. Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage. Br J Clin Pharmacol. 2019;85:2126–33.
Article CAS PubMed PubMed Central Google Scholar
Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891–8.
Arnaud M, Salvo F, Ahmed I, Robinson P, Moore N, Bégaud B, et al. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases. Drug Saf. 2016;39:251–60.
Article CAS PubMed Google Scholar
Caster O, Juhlin K, Watson S, Norén GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf. 2014;37:617–28.
Article CAS PubMed PubMed Central Google Scholar
Lacroix C, Salvo F, Gras-Champel V, Gautier S, Massy N, Valnet-Rabier M-B, et al. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge. Therapie. 2021;76:297–303.
Article PubMed PubMed Central Google Scholar
Khouri C, Revol B, Lepelley M, Mallaret M, Cracowski J-L. Impact of the “French Levothyrox crisis” on signal detection in the World Health Organization pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2018;27:1427–8.
Viard D, Parassol-Girard N, Romani S, Van Obberghen E, Rocher F, Berriri S, et al. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox® amidst a drug media crisis: atypical profile as compared with other drugs. Fundam Clin Pharmacol. 2019;33:463–70.
Article CAS PubMed Google Scholar
MedDRA | [Internet]. [cited 2019 Jan 23]. Available from: https://www.meddra.org/
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309.
Article CAS PubMed Google Scholar
Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol. 2015;68:950–6.
Micallef B, Dogné J-M, Sultana J, Straus SMJM, Nisticò R, Serracino-Inglott A, et al. An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance. Drug Saf. 2023;
Vidlin S. Unmasking data in the COVID-19 vaccine era [Internet]. Upps. Rep. 20230201 [cited 2023 Sep 21]. Available from: https://www.uppsalareports.org/articles/unmasking-data-in-the-covid-19-vaccine-era/
Harpaz R, DuMouchel W, Van Manen R, Nip A, Bright S, Szarfman A, et al. Signaling COVID-19 Vaccine Adverse Events. Drug Saf. 2022;45:765–80.
Article CAS PubMed PubMed Central Google Scholar
Adopo D, Daynes P, Benkebil M, Debs A, Jonville-Berra AP, Polard E, Patient involvement in pharmacovigilance: determinants and evolution of reporting from, et al. to 2020 in France. Eur J Clin Pharmacol. 2011;2022:1–8.
Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E. The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. Drug Saf. 2017;40:607–14.
Article PubMed PubMed Central Google Scholar
Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform. 2020;4:1059–71.
Mathieu C, Pambrun E, Bénard-Laribière A, Noize P, Faillie J-L, Bezin J, et al. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study. Eur J Epidemiol. 2022;37:1049–59.
Article CAS PubMed PubMed Central Google Scholar
Mathieu C, Bezin J, Pariente A. Impact of COVID-19 epidemic on antihypertensive drug treatment disruptions: results from a nationwide interrupted time-series analysis. Front Pharmacol. 2023;14:1129244.
Article PubMed PubMed Central Google Scholar
Hauben M, Hung E. Effects of the COVID-19 Pandemic on Spontaneous Reporting: Global and National Time-series Analyses. Clin Ther. 2021;43:360-368.e5.
Article CAS PubMed Google Scholar
Dörks M, Jobski K, Hoffmann F, Douros A. Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system. Pharmacoepidemiol Drug Saf. 2021;30:707–15.
Comments (0)